


Supplementary materials

Suppl. Table S1. Clinicopathological characteristics of 30 patients with hepatocellular carcinoma

| Parameters | Number of cases |
|--------------------------------|-----------------|
| Gender | |
| Female | 9 |
| Male | 21 |
| Age (years) | |
| <60 | 11 |
| ≥60 | 19 |
| AFP | |
| <400 | 11 |
| ≥400 | 19 |
| Tumor size (5 cm) | |
| <5 | 10 |
| ≥5 | 20 |
| Differentiation | |
| High/moderate | 10 |
| Poor | 20 |
| Venous invasion | |
| Negative | 14 |
| Positive | 16 |
| Clinical stage | |
| I | 6 |
| II-IV | 24 |
| T stage | |
| T ₁ -T ₂ | 17 |
| T ₃ -T ₄ | 13 |
| N stage | |
| N ₀ | 8 |
| N ₁ | 22 |
| M stage | |
| M ₀ | 12 |
| M ₁ | 18 |
| Survival status | |
| Alive | 12 |
| Dead | 18 |

Suppl. Table S2. Primer sequences used for qRT-PCR

| Gene | Forward primer sequence (5'-3') | Reverse primer sequence (5'-3') | Source |
|----------------|---------------------------------|---------------------------------|-----------------------|
| miR-500a-3p | UAAUCCUUGCUACCUGGGUGAGA | ACGUGACACGUUCGGAGAATT | miRBase: MIMAT0030415 |
| SOCS2 | GGAGGACGGATGACAAAGTC | AGACACTCTCCGGACTGAGG | NCBI: XM_054373709.1 |
| β -actin | CTCCATCCTGGCCTCGCTGT | GCTGCTACCTTCACCGTTCC | NCBI: NM_001101.5 |
| U6 | CGCTTCGGCAGCACATATAC | CGAATTTGCGTGTCATCCTT | NCBI: NR_004394.1 |



Suppl. Fig. S1. Determination of Fedratinib and EPO treatment concentrations (IC₅₀ measurement and selection of non-cytotoxic doses)

After Fedratinib treatment, the IC₅₀ values for HCCLM3 and MHCC97 cells were 1.65 μ M and 4.03 μ M, respectively, whereas the IC₅₀ values for EPO treatment were 1793 U/mL and 1616 U/mL, respectively. Under treatment with 0.2 μ M Fedratinib and 200 U/mL EPO, the viabilities of both cell lines at 24 h, 48 h, and 72 h did not differ significantly from those of the untreated group (Fig. 5C–D); therefore, these concentrations were used in subsequent experiments.